Table 2. Hit validation criteria.
| Compound | Assay 1 | Assay 2 | Analytically validated | Potency
a
|
Chemical liabilities | |
| Cell line | IC50 (μM) | |||||
| C1 (ref. 6 and 20–23) | IP | DSF | Yes | MCF-7 | 8.0 | Yes |
| T47D | 5.0 | |||||
| 501 Mel | 30.0 | |||||
| KSM-11 | 1.84 | |||||
| ARP-1 | 3.84 | |||||
| JeKo-1 | 4.8 b | |||||
| C2 (ref. 6 and 20) | IP | No | Yes | JeKo-1 | 9.3 | Unclear |
| ECC-1 | 14.3 b | |||||
| Compound #25 (ref. 7) | IP | LC-MS/MS | Yes | 8 cancer lines | 1.22–10.5 | Yes |
| Compound A (ref. 8) | IP | No | Yes | RPMI 8226 | 8.0 | No |
| U266 | 4.2 | |||||
| MM1.S | 5.4 | |||||
| ANBL6 | 10.0 | |||||
| RPMI 8226/LR5 | 6.3 | |||||
| RPMI 8226/Dox40 | 8.5 | |||||
| U266/LR6 | 4.3 | |||||
| MM1.RL | 5.4 | |||||
| ANBL-6/B7R | 8.0 | |||||
| 22d (ref. 9) | ELISA | No | Yes | H1299 | 1.05 | No |
| A549 | 1.49 | |||||
| Linichlorin A (ref. 11) | ELISA | No | Yes | HeLa | 3.2 | Yes |
| tsFT210 | 1.6 | |||||
| NIH3T3 | 12.7 | |||||
| Gentian violet (ref. 11) | ELISA | No | Yes | HeLa | 0.4 | No |
| tsFT210 | 0.6 | |||||
| NIH3T3 | 5.3 | |||||
| NSC689857 (ref. 10) | AlphaScreen | No | Yes | In vitro Skp2–Cks1 | 36.0 | Yes |
aPotency has been identified in cell proliferation or viability assays except where noted.
bEC50 value.